Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02316314 · ClinicalTrials.gov registry record
Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA)
A clinical trial of Friedreich's Ataxia, sponsored by Weill Medical College of Cornell University.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT02316314: Recruiting study of Friedreich's Ataxia, sponsored by Weill Medical College of Cornell University.
NCT02316314 is a study of Friedreich's Ataxia that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 100 participants, above the 60-participant average among 5 other Friedreich's Ataxia trials with a reported enrollment target (67% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02316314, a study of Friedreich's Ataxia, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Friedreich's ataxia (FRDA) is an autosomal recessive disease characterized by loss of coordination and cardiomyopathy. It is the most common form of inherited ataxia with an incidence in 1/50,000 in the Caucasian population. FRDA is associated with progressive damage to the nervous system, resulting in symptoms ranging from gait disturbance to speech problems, as well as diabetes and heart disease. The heart disease manifests as cardiomyopathy, and is responsible for approximately 60% of deaths from FRDA. This study is designed to characterize the cardiac manifestations of the disease using exercise, MRI, ECHO and serum parameters, in the context of the neurological disease. In addition, this study will demonstrate that corneal confocal microscopy (CCM) may also provide a biomarker for FRDA.
Primary Outcome
Average the levels of troponin for each subject
Conditions Studied
Interventions
- PROCEDURE Cardiac magnetic resonance imaging (CMR)
- PROCEDURE Exercise-stress test
- PROCEDURE Echocardiogram (ECHO)
- PROCEDURE Cardiac-related blood studies
Study Locations (1)
New York
- Weill Cornell Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2015-01-15 |
| Est. Completion | 2026-08 |
What NCT02316314 shows while recruiting
NCT02316314 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 5 other Friedreich's Ataxia trials with a reported enrollment target (67% higher).
The record links to 1 condition, with Friedreich's Ataxia appearing as the primary indexed condition, and to 4 interventions - of which Cardiac magnetic resonance imaging (CMR) is the first listed.
NCT02316314 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02316314 about?
NCT02316314 is a clinical study titled "Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA)". Friedreich's ataxia (FRDA) is an autosomal recessive disease characterized by loss of coordination and cardiomyopathy. It is the most common form of inherited ataxia with an incidence in 1/50,000 in the Caucasian population. FRDA is associated with progressive damage to the nervous system, resulting...
What is the current status of trial NCT02316314?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2015-01-15. Estimated completion is 2026-08.
What conditions does trial NCT02316314 study?
This clinical trial studies the following conditions: Friedreich's Ataxia.
What interventions are being tested in trial NCT02316314?
The interventions under investigation include: Cardiac magnetic resonance imaging (CMR) (PROCEDURE), Exercise-stress test (PROCEDURE), Echocardiogram (ECHO) (PROCEDURE), Cardiac-related blood studies (PROCEDURE).
Who is sponsoring clinical trial NCT02316314?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02316314 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Friedreich's Ataxia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Biomarkers in Friedreich's Ataxia
RECRUITING
-
Safety and Pharmacology Study of VP 20629 in Adults With Friedreich's Ataxia
COMPLETED · Phase 1
-
EPI-743 in Friedreich's Ataxia Point Mutations
COMPLETED · Phase 2
-
A First in Human Study of RT001 in Patients With Friedreich's Ataxia
COMPLETED · Phase 1
-
Preliminary Study of the Scale To Assess Ataxia and Neurologic Dysfunction (STAND)
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI